Paper of the day - Combined heart drugs risk
Combined ARB and ACE inhibitor treatment for heart failure markedly increases adverse effects compared with ACE inhibitor treatment alone, a meta-analysis has concluded.
US researchers looked at four studies involving 17,337 patients with an average of 25 months follow-up.
Patients with chronic heart failure taking an ARB/ACE inhibitor combination were 38% more likely to discontinue treatment due to adverse effects.
They also had double the risk of worsening renal function; almost five times the risk of hyperkalemia and a 50 per cent increased risk of symptomatic hypotension.
Arch Intern Med 2007; 167: 1930-1936